Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07101328 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 215
- Enrollment target
NCT07101328: Recruiting Phase 1 study, sponsored by Eli Lilly and Company.
NCT07101328 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 215 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07101328, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 215 participants
- Enrollment target
Study Summary
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Interventions
- DRUG LY4152199 - IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
What NCT07101328 shows while recruiting
NCT07101328 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (258% higher).
The record links to 0 conditions, and to 1 intervention - of which LY4152199 - IV is the first listed.
NCT07101328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07101328 about?
NCT07101328 is a clinical study titled "A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )". The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
What is the current status of trial NCT07101328?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2026-05-28. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07101328?
The interventions under investigation include: LY4152199 - IV (DRUG).
Who is sponsoring clinical trial NCT07101328?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07101328's enrollment target sits among peer trials
215 243rd of 2000 higher than 1,757 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI